Vanda Pharmaceuticals (NASDAQ:VNDA) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on the stock. Cantor Fitzgerald lifted their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. HC Wainwright started coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They issued a “buy” rating and a $18.00 target price on the stock.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $4.92 on Friday. Vanda Pharmaceuticals has a 1 year low of $3.44 and a 1 year high of $6.75. The firm has a market cap of $286.89 million, a PE ratio of -17.57 and a beta of 0.77. The company has a 50 day simple moving average of $4.80 and a two-hundred day simple moving average of $5.27.

Insider Activity at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total value of $25,850.00. Following the sale, the director now owns 44,857 shares in the company, valued at approximately $231,910.69. This represents a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of VNDA. Barclays PLC increased its position in shares of Vanda Pharmaceuticals by 128.2% during the third quarter. Barclays PLC now owns 154,297 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 86,677 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Vanda Pharmaceuticals by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock worth $6,689,000 after purchasing an additional 94,870 shares in the last quarter. ClearAlpha Technologies LP raised its stake in shares of Vanda Pharmaceuticals by 50.0% in the third quarter. ClearAlpha Technologies LP now owns 60,000 shares of the biopharmaceutical company’s stock worth $281,000 after purchasing an additional 20,000 shares during the last quarter. Verition Fund Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 7.8% during the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 2,927 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Vanda Pharmaceuticals by 1,184.6% during the third quarter. BNP Paribas Financial Markets now owns 62,238 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 57,393 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.